Summary of the project for the planned application:
The present Eurostars application seeks to explore salmon roe substances (Vernex) as a topical immunological treatment of mild to moderate psoriasis (3-10% body area affected) based on a working hypothesis of a novel, safe, low cost IL-1b inhibitor treatment option, used alone or in combination with systemic immunotherapy.
As we have was previously shown that Vernex work in orchestrating keratinocyte re-epithelialization in human wounds, we will, based on these findings explore its potential modulating effect in the hyperkeratinocytic pathogenesis of psoriasis by virtue of its very strong IL-1b inhibitory effect (Regenics' data). We will primarily perform more pre-clinical documentation, but the main work packages will be a clinical intervention study in mild to moderate psoriasis (n=30-40).